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Altered histone acetylation is associated with several
diseases, including cancer. We report here that,
unlike in most cancers, histones are found to be
highly hyperacetylated in oral squamous cell carci-
noma (OSCC; oral cancer) patient samples. Mecha-
nistically, overexpression, as well as enhanced
autoacetylation, of p300 induced by nucleophosmin
(NPM1) and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) causes the hyperacetylation, which
is nitric oxide (NO) signal dependent. Inhibition of
the histone acetyltransferase (HAT) activity of p300
by awater-soluble, small molecule inhibitor, Hydrazi-
nocurcumin (CTK7A), substantially reduced the
xenografted oral tumor growth in mice. These re-
sults, therefore, not only establish an epigenetic
target for oral cancer, but also implicate a HAT inhib-
itor (HATi) as a potential therapeutic molecule.
INTRODUCTION
Chromatin is a dynamic entity that plays a critical role in nucleus-
related phenomena such as transcription, replication, and
repair (Carrozza et al., 2003). Posttranslational modifications of
chromatin play an important role in maintaining chromatin struc-
ture-function and hence regulate gene expression, cell growth,
and differentiation. Increasing evidence suggests that chromatin
structure-function has a pivotal role in several disease manifes-
tations (Thorne et al., 2009). This is evident from the fact that
genetic alterations and/or a more diverse group of epigenetic
changes may result in cancer development and other diseases
(Thorne et al., 2009; Fraga et al., 2005; Varambally et al., 2002;
Seligson et al., 2005; Das et al., 2009; Pfister et al., 2008; Esteller,
2007; Bhaumik et al., 2007).
Of the various histone acetyltransferases (HATs), the global
transcriptional coactivator p300 (Debes et al., 2003) has been
observed to have altered expression in a few tumors. For
example, some tumors show higher levels of p300 (Debes
et al., 2003; Ishihama et al., 2007), some primary tumors and
cell lines exhibit mutations in p300 acetyltransferase (GaytherChemistry & Biology 17, 90et al., 2000), and loss of heterozygocity at the p300 locus has
been shown to be associated with colorectal, breast, and brain
cancer (glioblastoma) (Gayther et al., 2000; Van Beekum and
Kalkhoven, 2007). Although these data indicate the involvement
of the p300 gene, the enzyme (acetyltransferase) activity has not
been established as the cause of malignancy (Van Beekum and
Kalkhoven, 2007).
Recently, alterations of histone modifications have been re-
ported in different cancers. The loss of Lys 16 acetylation and
Lys 20 methylation of H4 were found to be associated with
primary tumors and tumor cell lines (Fraga et al., 2005). In
another study, changes in bulk histone modifications of cancer
cells were found to be predictive of the clinical outcome of
prostate cancer (Seligson et al., 2005). However, a rare excep-
tion of histone hyperacetylation has been observed in hepatocel-
lular carcinoma (Bai et al., 2008). Apart from cancer, dysfunction
of lysine acetyltransferases has been implicated in other dis-
eases such as inflammatory processes, Huntington’s disease,
cardiac disease, and diabetes (Davidson et al., 2005; Zhou
et al., 2004; Rouaux et al., 2003). These observations suggest
that specific and relatively nontoxic inhibitors of acetyltrans-
ferases could be considered as new generation therapeutic
agents for cancer. Although several HAT inhibitors have been
discovered (Selvi and Kundu, 2009; Cole, 2008) with a potential
therapeutic importance in HIV and cardiac disease (Davidson
et al., 2005; Mantelingu et al., 2007; Balasubramanyam et al.,
2004; Morimoto et al., 2008), the effect of HAT inhibitors on
cancer manifestation has not yet been tested.
The hallmark of cancer is hyperproliferative cells, which have
evaded the cellular apoptotic machinery and hence, exhibit
overexpressed antiapoptotic proteins. NPM1 (also known as
B23) (Grisendi et al., 2006; Shandilya et al., 2009) and GAPDH
(Altenberg and Greulich, 2004) are two such genes that are
known to be frequently upregulated in many cancers, including
oral cancer. Both of these proteins are suggested to be positive
regulators of cell proliferation.
Here, we report that histone H3 is hyperacetylated in oral
cancer patient samples and is positively correlated with upregu-
lated NPM1 and GAPDH protein levels. We also present a novel
mechanism to explain how hyperacetylation of H3 could be
regulated by NPM1 and GAPDH in a NO-dependent manner
involving p300 acetyltransferase. Furthermore, we show that a
novel water-soluble HATi, CTK7A, inhibits oral tumor cell growth
in nude mice.3–913, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 903
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Histone H3 Is Hyperacetylated in Oral Cancer
To investigate the histone acetylation status in different cancers,
histones were isolated from different cell lines and subjected to
immunoblotting analysis with antiacetylated histone H3 (anti-
H3AcK9AcK14) antibodies. We observed that histones are
predominantly hyperacetylated in oral (KB, OSCC cell) and liver
(HepG2) cancer cell lines (Figure 1A). Histone hypoacetylation is
a hallmark of cancer, except hepatocarcinoma (Bai et al., 2008).
The enhanced H3 acetylation in the oral cancer cell line was
paradoxical yet interesting. These results, therefore, led us to
examine the acetylation levels of histone H3 in the tissues
obtained from grade II OSCC (tumor samples from this grade
were readily available) patients by immunohistochemistry (IHC)
(Figure 1B; also see Table S1 available online) and immunoblot-
ting (Figure 1C) analyses using specific antibodies. The immu-
nostaining revealed that histone H3 (predominantly H3K14) is
hyperacetylated in the cancerous tissues in comparison to the
adjacent normal tissue (Figure 1B). As H3K14 is the predominant
in vivo target of p300-mediated acetylation (Kouzarides, 2007),
we next investigated the expression level of p300, which was
found to be significantly overexpressed in the malignant tumor
as compared to the adjacent normal tissue (Figure 1B). Overex-
pression of p300 was also confirmed by real-time RT-PCR anal-
ysis of RNA isolated from patient samples (Figure S1). Other
HATs such as CBP and PCAF showed no significant change
asmonitored by IHC andRT-PCR analysis (Figure 1B; Figure S1).
These results suggest that highly active acetylated p300 could
be involved in the histone hyperacetylation in malignant oral
tumors. Because autoacetylation of p300 enhances its acetyl-
transferase activity (Thompson et al., 2004), the autoacetylation
status of p300 was also verified using a polyclonal antibody,
which specifically recognizes acetylated p300 (ac-p300) mole-
cules (Thompson et al., 2004). Interestingly, p300 was found to
be hyperacetylated in oral cancer samples (Figure 1B).
Autoacetylation of p300 could be enhanced by several factors
(Thompson et al., 2004; Sen et al., 2008; Hansson et al., 2009;
Turnell et al., 2005; Huang and Chen, 2005), some of which are
overexpressed in different cancers. We found that GAPDH, an
enhancer of p300 autoacetylation (Sen et al., 2008), is signifi-
cantly overexpressed in the oral tumor tissues as compared
with the control (Figure 1B). As reported recently (Shandilya
et al., 2009), a concomitant increase of NPM1was also observed
in these patient samples (Figure 1B). Subsequently, we took six
different pairs of tissue samples (tumor and corresponding
adjacent normal tissue) and determined the levels of protein
overexpression by immunoblotting analyses. In all of the
samples, histone H3 was hyperacetylated as probed by anti-
H3AcK9AcK14 acetylation-specific antibody (Figures 1B and
1C). Interestingly, we also observed the hyperacetylation of
H2AK5 andH3K56 (Figures 1B and 1C), other p300-specific sites
which suggest further the role of p300-mediated acetylation. The
levels of acH4K16 (Figures 1B and 1C) were found to be signifi-
cantly low in the oral tumor samples, as observed in several
cancers (Fraga et al., 2005). However, the H4K8 acetylation
wasminimally altered (Figures 1B and 1C). Furthermore, GAPDH
andNPM1were also found tobeoverexpressed in all of the tumor
tissue samples (Figures 1B and 1C). Collectively, these data904 Chemistry & Biology 17, 903–913, August 27, 2010 ª2010 Elsevisuggest that the overexpression of GAPDH and NPM1 are posi-
tively correlated to histone hyperacetylation in oral cancer. An
interesting question raised at this juncture: is there any system-
atic molecular correlation of p300 autoacetylation and overex-
pression of these proteins that could be cell signal driven?
NO-Induced Histone Acetylation is Associated
with NPM1 and GAPDH Overexpression via p300
Autoacetylation
The free radical gas NO is generated by the nitric oxide synthase
(NOS) family of enzymes. NO is a pleiotropic signaling molecule
that has been identified as a mediator for numerous physiolog-
ical and pathophysiological conditions (Moncada et al., 1991).
Because increased production of NO was noticed in oral cancer
with a simultaneous upregulation of inflammatory (predomi-
nantly, NFk-B-responsive) genes (Gallo et al., 1998; Czesnikie-
wicz-Guzik et al., 2008), we hypothesized that NO signaling
could be the link to overexpression of NPM1 and GAPDH, which
in turn induces autoacetylation of p300, followed by hyperacety-
lation of histones. Immunohistochemical analysis revealed that
indeed the inducible nitric oxide synthase (iNOS) levels were
significantly enhanced in tumor tissue samples (Figure 2A).
COX2 levels were also found to be higher in these tumor tissue
samples (Figure 2A). A recent report implicates NO-dependent,
nuclear localized GAPDH as an enhancer of p300 autoacetyla-
tion and thereby its catalytic activity (Sen et al., 2008). In the
oral cancer patient samples analyzed, GAPDH was predomi-
nantly localized to the nucleus (Figure 2A). To investigate the
causal relationship of iNOS and overexpression of NPM1 and
GAPDH, KB cells were treated with the NO donor, S-nitrosoglu-
tathione (GSNO). It was observed that the expression of both
NPM1 and GAPDH was enhanced by GSNO in a concentra-
tion-dependent manner (Figure 2B; see also Figure S2). In agree-
ment with the previous report (Sen et al., 2008), we also found
that GAPDH is acetylated in a NO-dependent manner (Fig-
ure 2C). Interestingly, acetylation of NPM1 was also dramatically
enhanced by GSNO treatment in KB cells (Figure 2C). Similar
results were observed upon GSNO treatment in HeLa and
KOSC-2 cells (see Figure S2).
In order to gain insight into signaling pathways, we investi-
gated the effect of interferon-g (IFN-g) on NPM1 and GAPDH
acetylation in KB cells, as it is known to activate iNOS gene
expression to produce NO (Fukumura et al., 2006). We found
that IFN-g efficiently enhanced the NPM1 and GAPDH acetyla-
tion in a NO-dependent manner in KB (Figure 2D), HeLa, and
KOSC-2 cells (Figure S2), which was abolished or reduced in
the presence of a specific iNOS inhibitor, N-(3-(Aminomethyl)
benzyl)acetamidine (1400 W). Furthermore, we found that
IFN-g treatment could induce the translocation of the cytosolic
protein GAPDH to the nucleus of KB cells (Figure 2E) and HeLa
and KOSC-2 cells (Figure S2). Taken together, these results
suggest the involvement of NO signaling in the overexpression
of NPM1 and GAPDH and their acetylation in KB cells.
GAPDH, which is positively regulated by NO signaling,
enhances the autoacetylation of p300 (Sen et al., 2008) and
presumably leads to histone hyperacetylation. These observa-
tions prompted us to investigate the role of NPM1 in the activa-
tion of p300 (autoacetylation). p300 autoacetylation reaction was
performed in the presence of NPM1 and 3H-acetyl-CoA. NPM1er Ltd All rights reserved
AcH2AK5
H3
AcH4K8
AcH3K14
AcH3K9
AcH3K56
AcH4K16
H
E
K
 2
9
3
T
H
e
L
a
K
B
H
e
p
G
2
A
5
4
9
K
O
S
C
-
2
Anti-NPM1
Anti-GAPDH
Anti-Tubulin
Anti-AcH3
Anti- H3
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
N    T     N     T    N    T     N     T    N    T     N     T
N = Normal
T = Tumor
Anti-AcH2AK5
Anti-AcH4K16
Anti-AcH4K8
Anti-AcH3K56 AcH3 GAPDHNPM1
Normal
Tumor
A
r
b
it
r
a
r
y
 
u
n
it
s
0
5
10
15
20
25
P = 0.012 
P = 0.023 
P = 0.01 
AcH2AK5 AcH4K16
P = 0.035 
P = 0.045 
AcH3K56 AcH4K8
P = 0.043 
P = 0.069 
A
C
B
ac-p300
H3AcK14
H3 AcK9
Tumor Normal
p300
GAPDH
NPM1
H2A AcK5
H4AcK16
%
In
c
r
e
a
s
e
in
H
4
A
c
K
1
6
0
25
50
75
100
P = 0.037
%
In
c
r
e
a
s
e
in
H
2
A
A
c
K
5
0
25
50
75
100
P = 0.04
%
In
c
r
e
a
s
e
in
N
P
M
1
0
25
50
75
100 P = 0.005
%
In
c
r
e
a
s
e
in
G
A
P
D
H
0
25
50
75
100 P = 0.005
%
In
c
r
e
a
s
e
in
a
c
-
p
3
0
0
0
25
50
75
100
P = 0.023
%
In
c
r
e
a
s
e
in
H
3
A
c
K
9
0
25
50
75
100
P = 0.065
%
In
c
r
e
a
s
e
in
H
3
A
c
K
1
4
0
25
50
75
100
P = 0.006
Normal
Tumor
%
In
c
r
e
a
s
e
in
p
3
0
0
0
25
50
75
100
P = 0.032
PCAF
H3AcK56
H4AcK8
Tumor Normal
CBP
Tubulin
%
 I
n
c
r
e
a
s
e
 i
n
 
P
C
A
F
0
25
50
75
100
P = 0.068 
%
 I
n
c
r
e
a
s
e
 i
n
T
u
b
u
li
n
0
25
50
75
100 P = 0.07 
%
 I
n
c
r
e
a
s
e
 i
n
 C
B
P
0
25
50
75
100
P = 0.06 
%
 I
n
c
r
e
a
s
e
 i
n
H
4
A
c
K
8
0
25
50
75
100
P = 0.065 
Normal
Tumor
%
 I
n
c
r
e
a
s
e
 i
n
H
3
A
c
K
5
6
0
25
50
75
100
P = 0.009 
Figure 1. Histone Hyperacetylation Is Associated with Upregulation of NPM1 and GAPDH in Human Oral Cancer
(A) Histones are hyperacetylated in oral cancer cells. Histones were isolated from different cell lines as indicated and histone acetylation was analyzed by western
blotting with the indicated antibodies. Anti-H3 was used as a loading control.
(B) Immunohistochemical detection of histone acetylation and expression of different proteins in oral cancer samples. Representative images (403magnification)
are shown. Respective P values are shown, sample size; n = 27, mean ± SD, one-way ANOVA.
(C) Immunoblotting analysis to compare the protein levels and acetylation status of histone H3 in the tumor (T) and the adjacent normal tissue (N) of the different
patient samples (left). Tissue lysates were immunoblotted with anti-NPM1 and anti-GAPDH. Tubulin was used as a loading control. Histones isolated from the
same patient tissue were used for the western blotting using the indicated antibodies and anti-H3 was used as a loading control. Densitometric analysis (C, right)
of the data in (C, left) was done using phosphoimager (Fuji). Results are the mean ± SD, n = 6, one-way ANOVA. See also Figure S1 and Table S1.
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Histone Hyperacetylation in Oral Cancerwas found to activate the autoacetylation of p300 in a dose-
dependent manner (Figure 2F). GAPDH was used as a positive
control (Sen et al., 2008). In order to validate the results in vivo,
transient transfection of Flag-NPM1 was performed. NPMI was
found to be predominantly localized to the nucleolus of the cellsChemistry & Biology 17, 90while a minor fraction was also found to be present in the nucle-
oplasm (Figure S3A) as reported earlier (Shandilya et al., 2009).
Interestingly, we observed that the KB cells overexpressing
NPM1 had higher levels of acetylated histone H3, as observed
by coimmunofluorescence analysis (Figure S3A). Furthermore,3–913, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 905
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Figure 2. NO Enhances Acetylation of Histone and Nonhistone Proteins
(A) Immunohistochemical detection of GAPDH, iNOS, and COX2 expression in human oral cancer (as done in Figure 1A). Arrows indicate the nuclear localization
of GAPDH in the tumor sample (inset; 1003 magnification) as compared with adjacent normal cells. Representative images (403 magnification) are shown.
Respective P values are shown, n = 27, mean ± SD, one-way ANOVA.
(B) GSNO induces expression of NPM1 and GAPDH. KB cells were treated with the indicated concentration of GSNO for 24 hr. Cell lysates were used to perform
the western blotting using an anti-NPM1 and anti-GAPDH antibody. Tubulin was used as a loading control.
(C) NO induces the acetylation of NPM1 and GAPDH. KB cells were grown in the presence of 200 mM GSNO or GSH for 24 hr. Cell lysates were immunoprecip-
itated (IP) with anti-acetyl lysine antibody and the immunoprecipitates were analyzed by western blotting with anti-NPM1 (left panel) and anti-GAPDH (right)
antibodies.
(D) IFN-g treatment enhances acetylation of NPM1 (left) and GAPDH (right), which is abolished by the iNOS inhibitor 1400 W (100 mM). IP was performed as
described above.
(E) GAPDH translocates to the nucleus of KB cells after exposure to IFN-g (10 ng/ml) for 16 hr and stainedwith anti-GAPDH antibody (green) and 40,6-diamidino-2-
phenylindole dihydrochloride (DAPI; blue). Red arrows indicate the nuclear GAPDH. Experiment was performed two times. Representative figure is shown. Scale
bars, 10 mm.
(F) NPM1 (600 ng) and GAPDH enhances the autoacetylation of full-length p300 (p300fl; 100 ng) in vitro (left) and in a concentration-dependent manner (300, 600,
and 900 ng of NPM1) (right) as shown by autoradiography.
(G) NO causes the hyperacetylation of histone H3K14. In vivo isolated histones from the GSNO-treated KB cells were immunoblotted with anti-acetylated H3K14
and anti-H3 antibody. Densitometric analysis (right panel) of the data was done using phosphoimager (Fuji).
P values are shown, n = 2, mean ± SD, one-way ANOVA. See also Figures S2–S6.
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Histone Hyperacetylation in Oral Cancerwestern blotting analysis also shows that NPM1 overexpression
could lead to concomitant increase in histone H3 and H4 acety-
lation, presumably due to enhanced autoacetylation of p300
mediated by NPM1(Figure S3B) .
In order to further confirm the role of NPM1 in the p300-medi-
ated acetylation, we also performed small interfering RNA
(siRNA)-mediated silencing of NPM1 for 48 hr in three different
cell lines (KB, HeLa, and KOSC-2 cells) (see Experimental
Procedures). The results show that indeed silencing of NPM1
significantly reduced histone H3 acetylation status (Figures S3C906 Chemistry & Biology 17, 903–913, August 27, 2010 ª2010 Elseviand S3D) which correlates with the reduction in the autoacety-
lated p300 (Figure S3C). The siRNA-mediated silencing of
GAPDH (Figure S4) and iNOS (Figure S5) also abrogated the
acetylation of p300 and histone H3 which suggest the involve-
ment of GAPDH and iNOS in p300-mediated acetylation upon
IFN-g treatment. The link of IFN-g treatment and p300-mediated
acetylation was further shown by employing a p300 HAT-
specific inhibitor plumbagin (RTK1) (Ravindra et al., 2009) (Fig-
ure S6). BecauseNO signaling induces the p300 autoacetylation,
we next investigated the role of NO. GSNO treatment of KB cellser Ltd All rights reserved
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Figure 3. CTK7A Is a Water-Soluble HATi
(A) Structural formula of CTK7A. Sodium 4-(3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)benzoate (left panel). Inhibition curves for various recombinant
HATs, HMTs, and HDACs (right). Reactions were done in duplicate and error bars reflect the SD from at least two independent experiments.
(B) Lineweaver-Burk plots showing mixed inhibition of p300 by CTK7A. Each experiment was performed three times, and reproducibility was within 15%.
Representative figure is shown.
(C) CTK7A inhibits p300fl (top) and PCAF autoacetylation (middle). Gel fluorography assay were performed using curcumin and DMSO as a positive and solvent
control respectively. Reaction mixtures were resolved on 8% SDS-PAGE. CTK7A inhibits p300 autoacetylation in KB cells as shown by IP assay (bottom). Cell
lysates were immunoprecipitated with anti-p300 antibody and control antibody (IgG). The immunoprecipitates were analyzed by western blotting with anti-p300
or anti-ac-p300 antibody (see Experimental Procedures for detail).
(D) CTK7A inhibits histone acetylation in KB cells. In vivo histones were isolated from CTK7A or curcumin-treated KB cells at the indicated concentration for 24 hr
and were immunoblotted with anti-acetylated H3 and anti-H3 antibody.
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Histone Hyperacetylation in Oral Cancerenhanced the level of H3K14 acetylation in a concentration-
dependent manner (Figure 2G), which was similar to the con-
comitant increase in NPM1 and GAPDH levels upon GSNO
treatment as mentioned above (Figure 2B). Taken together,
these data suggest that hyperacetylation of histones in oral
cancer could be achieved by the overexpressed and autoacety-
lated p300 in a NO-dependent manner.
CTK7A Is a HAT Inhibitor
These results clearly demonstrate that hyperactivity of lysine
acetyltransferase p300 could be one of the factors responsible
for oral cancer manifestation. Therefore, the inhibitor of p300
HAT activity would be useful to verify the possible involvement
of the acetyltransferase(s). We have previously shown that
curcumin is specific inhibitor of p300/CBP (Balasubramanyam
et al., 2004). Curcumin and several of its derivatives has beenChemistry & Biology 17, 90reported to have anticancer properties (Anand et al., 2008). How-
ever, among them, 4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-
ethyl]-4,5-dihydro-pyrazol-1-yl}-benzoic acid (also known as
HBC) has been shown to posses antiproliferative activities
against several human cancer cells (Shim et al., 2002). HBC
was further shown to inhibit the cell cycle progression of colon
cancer cells via antagonizing of Ca2+/calmodulin functions
(Shim et al., 2004). Using curcumin as a synthon, we first made
HBC and then in order to get a water-soluble derivative made
a salt of that, namely, CTK7A (Figure 3A). CTK7A was found to
inhibit HAT p300/CBP and PCAF but did not affect the activity
of other histone modifying enzymes like G9a, CARM1, Tip60,
HDAC1, and SIRT2, even at 100 mM (Figure 3A). Further kinetic
analysis revealed that CTK7A-mediated p300 inhibition follows
a mixed type of inhibition for both of the substrates, acetyl-
CoA, and core histones (Figure 3B). Replot of the slopes and3–913, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 907
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Figure 4. CTK7A Inhibits the Growth of KB Cells and Induces Senescence-like Growth Arrest
(A) CTK7A inhibits the growth of KB cells. Cell proliferation was examined by [3H]-thymidine incorporation assay after treatment with different concentrations
of CTK7A as indicated. Doxorubicin (100 mM) was used as a positive control. Each experiment was performed in duplicate and error bars reflect the standard
deviation from three independent experiments.
(B) CTK7A inhibits wound healing. Cells with wounds of constant diameter were treated with CTK7A (100 mM) for 24 hr along with 10% serum. The wound
photographs were taken under phase-contrast microscope. Serum positive (top) and negative (middle) cells act as positive and negative controls, respectively.
Each experiment was performed three times. Representative figure is shown.
(C) CTK7A induces polyploidy in KB cells. KB cells were incubated with the indicated doses of CTK7A for 24 hr and were analyzed by flow cytometry.
In CTK7A- (100 and 200 mM) treated cells, cell populations with DNA content >4N (polyploidy) were drastically increased compared with untreated KB cells
(control). Experiment was performed three times. Representative figure (data) is shown.
(D) CTK7A induces senescence-associated b-gal expression (SA-b-gal) in KB cells. KB cells were incubated with 100 mM of CTK7A for 24 hr. Cells were stained
for SA-b-gal. CTK7A treatment induces the SA-b-gal expression in treated cells (right) as compared with untreated, control (left). Experiment was performed two
times. Representative figure is shown.
(E) Immunoblot indicating levels of cyclin E upon CTK7A treatment in KB cells (left). ChIP analysis at the promoter of cyclin E after CTK7A treatment (100 mM) for
24 hr in KB cells (middle). ChIP was performed using antiH3 and anti-acetylated H3 antibodies. IgG was used as a control. A reChIP assay was also done by
carrying out first immunoprecipitation with anti-p300 and then anti-Ac-p300 antibody at the cyclin E promoter after CTK7A treatment (100 mM) for 24 hr in KB
cells. Values are relative to immunoprecipitated input DNA. Results are the mean ± SD of three independent ChIP experiments, one-way ANOVA. See also
Figure S7.
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Histone Hyperacetylation in Oral Cancerthe intercepts were linear. Kis for the acetyl-CoA and core
histone were 13.8 and 18.6 mM while Kii for the same were
110.6 and 67.8 mM, respectively. The presence of Kii > Kis further
confirms the occurrence of mixed type of inhibition with the
line intersecting above the abscissa. However, as expected,
CTK7A efficiently inhibited the autoacetylation of p300 and
PCAF (Figure 3C) in a concentration-dependent manner
in vitro. Furthermore, CTK7A also inhibited the enhanced autoa-
cetylation of p300, mediated by a cocktail of HDAC inhibitors in
KB cells (Figure 3C). To elucidate the effect of CTK7A on histone
acetylation in a cellular system, KB cells were treated with
CTK7A. As expected, it potently inhibited the acetylation of
histone H3 in KB cells (Figure 3D). These results suggest that
the water-soluble HATi, CTK7A, inhibits histone acetylation in
the cellular system at least partially through the inhibition of
p300 autoacetylation.908 Chemistry & Biology 17, 903–913, August 27, 2010 ª2010 ElseviCTK7A Inhibits Cell Proliferation and Induces
Senescence-like Growth Arrest
Because p300/CBP is a master regulator and is involved in the
regulation of cell cycle progression, proliferation, and differenti-
ation (Goodman and Smolik, 2000), we next investigated the
growth-inhibitory properties of CTK7A on KB cells. CTK7A
caused a dose-dependent inhibition of KB cells proliferation,
observed by thymidine-incorporation assay (Figure 4A). The anti-
proliferative activity of CTK7A was further assessed by a wound
healing assay. We observed that CTK7A-treated cells showed
a reduction in wound healing activity in the presence of serum
(Figure 4B). Cells with or without serum were used as positive
and negative controls, respectively (Figure 4B). These results
suggest an antiproliferative role of CTK7A in KB cells. Based
on the above results, the effect of CTK7A on cell cycle progres-
sion was also determined. KB cells, when treatedwith increasinger Ltd All rights reserved
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Figure 5. CTK7A Inhibits Xenograft Tumor Growth in Nude Mice
(A) Nude mice carrying the KB cell xenografts were treated with phosphate-
buffered saline (control) or with 100 mg/kg body weight CTK7A intraperitone-
ally twice a day. Tumor volumes (mm3) were determined as described in
Experimental Procedures. One-way ANOVA revealed that tumor sizes were
significantly different (p = 0.034, n = 16, mean ± SD).
(B) CTK7A inhibits histone acetylation in nude mice. KB cell tumors from
control and CTK7A-treated mice were used for immunohistochemical detec-
tion with indicated antibodies as performed earlier. Representative images
(403 magnification) are shown. Respective P values are shown, sample
size; n = 16, mean ± SD, one-way ANOVA. See also Figure S8.
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percentage of polyploid cells (>4N) in a concentration-depen-
dent manner (Figure 4C).
Induction of polyploidy is often associated with senescence,
which is known to be associated with antitumor processes
(Ota et al., 2006). We found that CTK7A induced the expression
of SA-b-gal, a marker for senescence (Figure 4D). This is consis-
tent to the earlier report in which the role of p300 in regulating
proliferation and senescence of human melanocytes was shown
using the p300 acetyltransferase activity specific inhibitor, Lys-
CoA (a substrate analog of acetyl-CoA) (Thompson et al.,
2004; Bandyopadhyay et al., 2002). Lys-CoA has been shown
to inhibit cell proliferation and induce senescence-like growth
arrest as monitored by the expression of SA-b-gal (Bandyopad-
hyay et al., 2002).
Cyclin E is a critical regulator of senescence. Overexpression
of cyclin E helps the cells to escape from BRG1- and RAS-
induced senescence (Bandyopadhyay et al., 2002). Given that
p300/CBP regulates the expression of many cell cycle genes
(Goodman and Smolik et al., 2000), we determined the effect
of CTK7A on the expression of cyclin E. We observed that
CTK7A downregulated cyclin E expression in a dose-dependent
manner in KB cells, whereas expression of cyclin D1wasmargin-
ally affected (Figure 4E). We have also tested the affect of other
HATi, namely, RTK1 and curcumin on the cyclin E expression
and found that they are able to inhibit the expression of the cyclin
E (Figure S7A). Previous reports suggest that cyclin E gene
expression in human tumor cells and in mouse embryonic
fibroblasts is regulated by reversible acetylation of promoter-
proximal histones (Bandyopadhyay et al., 2002; Sambucetti
et al., 1999). To address the effect of CTK7A on acetylation
status at the cyclin E promoter, chromatin immunoprecipitation
(ChIP) assays were performed, which clearly demonstrated
that CTK7A inhibited the acetylation of H3 at the cyclin E
promoter (Figure 4E). A sequential ChIP (reChIP) assay was
also performed with an anti-p300 antibody, followed by an
anti-ac-p300 antibody, to estimate the acetylation status of
p300 upon CTK7A treatment. reChIP assays showed the
presence of p300 at the cyclin E promoter and that the p300
autoacetylation is inhibited upon CTK7A treatment (Figure 4E).
Collectively, these results imply that cyclin E downregulation
could be a direct effect of CTK7A-mediated inhibition of p300/
CBP HAT activity. The FACS analysis shows an increase in the
pre-G1 peak upon the HATi treatment which indicate the cellular
apoptosis. In agreement with this observation, it was found that
the treatment of CTK7A could lead to activation of caspase-3,
a key effector molecule in the apoptosis pathway (Figure S7B).
Furthermore, we found that the HATi-mediated caspase activa-
tion leads to PARP cleavage (Figure S7B). However, we do not
observe induction of senescence and apoptosis in HeLa and
HEK293T cells (Figure S7C and S7D). We also observed
apoptosis with the p300 HATi RTK1 but not with the inactive
derivative RTK2 (data not shown).
CTK7A Inhibits Tumor Growth
The in vitro- and cell line-based studies prompted us to investi-
gate the effect of CTK7A on cell line-derived oral tumor growth in
xenografted mice. We found that CTK7A is not toxic to the mice
after intraperitoneal (i.p.) administration. There was no observedChemistry & Biology 17, 90weight loss at doses up to 100 mg/kg body weight twice a day
during 1 month of treatment (data not shown).The treatment of
CTK7A has no apparent toxicity in the animals as revealed by
the H&E staining (Figure S8A). In order to test the effect of
CTK7A on tumor growth, we inoculated KB cells (2 3 106 cells)
in nude mice in the right and left flanks and treated with
100 mg/kg body weight twice a day (see Experimental Proce-
dures). CTK7A showed strong antitumor activity. KB cell tumors
were about 50% smaller in mice treated with CTK7A than in
control mice (Figure 5A). The differences in the tumor size
between xenografts (control versus treated) were found to be
statistically significant (p = 0.034). The levels of H3 acetylation3–913, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 909
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Figure 6. Proposed Model to Explain the Putative Epigenetic
Signaling Pathway that Causes Hyperacetylation of Histone and
Nonhistone Proteins
NO triggers the upregulation of NPM1 and GAPDH, which in turn enhance the
autoacetylation of p300. Highly active p300 acetylates histones and histone
chaperone NPM1, which presumably enhances gene expression for oral
cancer manifestation.
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determined using IHC analysis of xenografted tumors. CTK7A-
treated mice tumors showed a marginal effect with respect to
p300 expression (Figure 5B). We observed that CTK7A
decreased the levels of H3K9, K14 acetylation (as probed by
anti-H3AcK9AcK14, anti-H3AcK14, and anti-H3AcK9 anti-
bodies) and ac-p300 (Figure S8B). CTK7A was found to inhibit
H3K14 acetylation more potently than H3K9 acetylation (Fig-
ure 5B). These data are consistent with the antiproliferative effect
of CTK7A on KB cells. Further, the levels of GAPDH, NPM1, and
iNOS were also found to be downregulated in CTK7A-treated
mice (Figure S8B), which could also be caused by the antiproli-
ferative effect of CTK7A. Moreover, the level of COX2, which is
induced in many cell types by mitogens, growth factors, cyto-
kine, and tumor promoters and has been implicated in many
cancers, including oral cancer (Fukumura et al., 2006), was also
found to be suppressed in CTK7A-treated tumors (Figure S8B).
We also observed downregulation of the proliferation marker,
Ki67, in CTK7A-treated tumors (Figure S8B), which further
support the antiproliferative nature of the HATi, CTK7A.
Taken together, all of these results suggest that the water-
soluble HATi, CTK7A, by virtue of its HAT-inhibitory and antipro-
liferative activity, could lead to the inhibition of tumor growth in
xenografted mice.
DISCUSSION
Although reversible acetylation of histone and nonhistone
proteins is one of the most well-studied epigenetic marks, the
regulation of enzymatic machinery involved in these phenomena
has gained attention only recently. Dysfunction of HDACs and
the consequent hypoacetylation of histone and nonhistone
proteins have been causally related to cancer manifestation in
a few cases (Bolden et al., 2006). Reports regarding dysfunction
of HATs and cancer are rather scarce. Here, we show that, in
OSCC, histone H3 (predominantly at K14) is hyperacetylated in
grade II oral tumors. Associated overexpression and hyperace-
tylation of p300 suggest that autoacetylation of p300 could be
one of the key factors responsible for histone hyperacetylation.
We found that the histone chaperone NPM1, which is also over-
expressed in the oral tumors (Shandilya et al., 2009), induces the
autoacetylation of p300, presumably through its protein chap-
erone activity (Szebeni and Olson, 1999). These results indicate
a new function of the multifunctional nucleolar protein, NPM1.
Furthermore, these studies also establish an epigenetic signal,
IFN-g-dependent NO synthesis, which could be acting as a basic
stimuli for the NPM1- and GAPDH-mediated enhanced autoace-
tylation of p300 and thereby the downstream effects (Figure 6).
The correlation of histone modifications (especially acetyla-
tion) and cancer manifestation is not yet well established.
However, in the case of prostate cancer (Seligson et al., 2005)
and hepatocarcinomas (Bai et al., 2008) altered histone modifi-
cations were observed but the molecular mechanisms (and the
enzymatic machineries) behind the altered modifications are
not yet elucidated. Recently, increased acetylation of H3K56,
a target of p300/CBP, was also observed in multiple cancers
(Das et al., 2009). We have demonstrated that the hyperacetyla-
tion of histones, a histone chaperone (NPM1) and the metabolic
protein, GAPDH, is caused by the hyperactive, autoacetylated910 Chemistry & Biology 17, 903–913, August 27, 2010 ª2010 Elsevip300. The unique positive loop involved in this process of hyper-
acetylation could be a common mechanism in certain types of
cancer manifestation.
Oral cancer is an inflammation-related disease. Inflammation
can lead to NO production that can impact the initiation and
progression stages of cancer (Fukumura et al., 2006). Our find-
ings also provide a link between NO production and overexpres-
sion of cell proliferative marker genes such as NPM1 and
GAPDH. These observations are consistent with the report in
which enhanced iNOS activity was detected in human tumor
cell lines (Jenkins et al., 1994; Asano et al., 1994) and in patient
tumor samples of various histogenetic origins (Fukumura et al.,
2006). NOS activity has also been found to be associated with
tumorigenesis, proliferation, and expression of important
signaling components linked to cancer development (Fukumura
et al., 2006). It is known that IFN-g, a proinflammatory cytokine,
activates iNOS to produce NO (Fukumura et al., 2006). We have
found that IFN-g treatment in an oral cancer cell line (KB cells)
induced NO production, the inhibition of which (IFN-g) repressed
acetylation of NPM1 and GAPDH. Our results show that the
IFN-g treatment enhanced the nuclear translocation of GAPDH,
which could be activating the p300 autoacetylation and thus its
HAT activity. Although similar nuclear localization of GAPDH
has been reported in other cases (Sen et al., 2008; Hara et al.,
2005), the molecular mechanisms that induce nuclear transloca-
tion of GAPDH in KB cells remain elusive. Overexpressed NPM1
and GAPDH (nuclear) enhanced the autoacetylation of p300,
which in turn induced histone hyperacetylation. The hyperacety-
lated histones and NPM1 may favor the expression of genes
responsible for oral cancer progression (Figure 6). NPM1- and
GAPDH-induced autoacetylation of p300 may also lead to the
formation of a more dynamic transcriptional preinitiation com-
plex (Black et al., 2006), facilitating transcription. The histone
chaperone activity of NPM1 may also be used for transcriptional
activation as reported earlier (Swaminathan et al., 2005). Ourer Ltd All rights reserved
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ylation of NPM1 augments its oncogenic potential and has been
implicated in oral cancer manifestation (Shandilya et al., 2009).
Cancer cells have a higher energy requirement and increased
ribosome biosynthesis. Increased levels of GAPDH and NPM1
may help in metabolic requirements and in ribosome biogenesis,
respectively, in oral cancer.
Here, we have shown that the p300/CBP HATi, CTK7A, could
efficiently inhibit oral tumor growth in xenografted mice. CTK7A
induced polyploidy and senescence-like growth arrest in the oral
cancer cell line. Induction of senescence is known to contribute
to the treatments of chemotherapy and ionization radiation
(Dimri, 2005). Promotion of polyploidy followed by senescence-
like growth arrest has also been documented for the p300/CBP-
specific HATi, Lys-CoA (Bandyopadhyay et al., 2002). Mechanis-
tically, inhibition of histone acetylation leads to the repression of
cyclin E expression, which is an important regulator of senes-
cence. We have also observed that CTK7A treatment leads to
the repression of histone acetylation, NPM1 expression, iNOS
production and a significant reduction in the tumor growth in
nude mice. Induction of apoptosis may also be partially respon-
sible for the observed antitumor activity of CTK7A.
Our current observations establish the causal relationship of
histone hyperacetylation and oral cancer manifestation. Most
significantly, this study elucidates the mechanisms of hyperace-
tylation and identifies a new candidate protein, NPM1, as a regu-
lator of p300. With the recent discoveries of several new HAT
inhibitors, these molecules are being recognized as potential
antineoplastic therapeutics (Selvi and Kundu, 2009; Cole, 2008).
In oral cancer, p300 acetyltransferase activity may be consid-
ered as an important target for therapy. However, the complete
epigenetic language that derives OSCC remains elusive.
SIGNIFICANCE
Dysfunction of epigenetic regulation has been linked to
many diseases. In the present study, we have found that
histones are hyperacetylated in malignant oral tumors due
to overexpression and hyperacetylation of histone acetyl-
transferase (HAT) p300. The autoacetylation of p300 is
induced by NPM1 and GAPDH, which are overexpressed in
the malignant oral tissue. Significantly, NPM1 is a factor
discovered in this study as a positive regulator of p300
autoacetylation. Furthermore, our studies establish the
interferon-g (IFN-g) dependent nitric oxide (NO) signal trans-
duction pathway as an epigenetic signal for the hyperacety-
lation in oral cancer. The inhibition of p300 acetyltransferase
activity by the newly synthesized HATi in the xenografted
nude mice system leads to the arrest of tumor growth which
could be a potential antineoplastic therapeutic strategies,
particularly in OSCC.
EXPERIMENTAL PROCEDURES
Reagents
Chemicals used were from Sigma unless stated otherwise.
Cell Culture, Whole-Cell, and Tissue Lysate Preparation
KB (oral squamous cell carcinoma) and HeLa cells weremaintained in Dullbec-
co’s modified Eagle medium (DMEM) while KOSC-2 (oral squamous cellChemistry & Biology 17, 90carcinoma) cells were maintained in RPMI 1640medium with 10% fetal bovine
serum (FBS) at 37Cwith a 5%CO2 atmosphere in a humidified incubator. For
IFN-g and GSNO treatment, KB cells were incubated in the presence of IFN-g
10 ng/ml for an additional 16 and 24 hr, respectively. Immunofluorescence
staining of cells for confocal microscopy was carried out as described previ-
ously (Shandilya et al., 2009). CTK7A treatment was done for 24 hr followed
by acid extraction of histone and immunoblotting as per standard protocol
(Balasubramanyam et al., 2004). For whole-cell and tissue lysate preparation,
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% Na-deoxycholate,
150 mM NaCl, EDTA 1 mM, phenylmethylsulfonyl fluoride [PMSF], 1 mM
Na3VO4, 1 mM NaF, and protease inhibitor cocktail [Roche]) was used.
Transfection Assay
Transient transfections were carried out with 70%–80% confluent KB cells for
36 hr by using lipofectamine (Invitrogen) according to the manufacturer’s
protocol. The pCMV-Flag mammalian-NPM1 construct was described before
(Shandilya et al., 2009).
Immunoprecipitation Assay
Whole-cell extract were prepared using RIPA buffer as mentioned above. The
preblocked protein-G Sepharose-bound antibody (as indicated) (4 mg) was
incubated with 500 mg whole-cell lysate overnight at 4C. After extensive
washes, bead-bound proteins were analyzed by western blotting with indi-
cated antibodies. For HDAC inhibitors treatment, 5 mM sodium butyrate,
5 mM nicotiamide, and 100 ng/ml TSA were added 10 hr before cells were
harvested (Thompson et al., 2004). IgG was used as a control.
Chromatin Immmunoprecipitation Assay
The ChIP and re-ChIPassays was performed as described earlier (Shandilya
et al., 2009; Bandyopadhyay et al., 2002) using indicated antibodies. KB cells
were treated with CTK7A and cells were grown for 24 hr. Real-time PCR
analysis was performed using primers for the cyclin E promoter region:
50-GGCGGGACGGGCTCTGGG-30 and 50-CCTCGGCATGATGGGGCTG-30.
Chemical Synthesis
CTK7A was synthesized as described in Supplemental Experimental
Procedures.
HAT, HDAC, and HMTase Assay
In vitro acetylation, deacetylation and methyltransferase assays were
performed as previously reported (Mantelingu et al., 2007; Balasubramanyam
et al., 2004). For SirT2 deacetylase assay, 50 ng of bacterially expressed,
recombinant enzymewas added in the presence or absence of cofactor NAD+.
Kinetic analysis of p300 HAT inhibition was performed as reported earlier
(Balasubramanyam et al., 2004) in the presence of (0, 30, 40, and 50 mM)
CTK7A. The obtained values were plotted as a lineweaver burk plot using
Graph pad Prism software. For p300 autoacetylation assay, reactions of
p300 full-length (80 ng) were carried out in HAT assay buffer at 30C for
10 min with or without the protein (NPM1) followed by addition of 2 ml of
4.7 Ci/mmol 3H-acetyl-CoA (NEN-PerkinElmer) and were further incubated
for another 10 min in a 30 ml reaction. GAPDH was used as positive control
(Sen et al., 2008). The radiolabeled acetylated p300 were processed by
fluorography followed by autoradiography. p300 or PCAF autoacetylation
inhibition assay were performed under similar reaction conditions as
described above with minor changes. HATi were added in place of protein
substrate and 1 ml of 4.7 Ci/mmol 3H-acetyl-CoA was used.
Cell-Based Assays
Senescence-associated b-gal (SA-b-gal) activity analysis was performed as
described earlier (Bandyopadhyay et al., 2002). Immunofluorescence assay
was performed as previously described (Shandilya et al., 2009).
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